Mogamulizumab is a humanized monoclonal antibody targeting CCR4, a chemokine receptor expressed on T-cells, including malignant cells found in cutaneous T-cell lymphoma (CTCL). CTCL represents a heterogeneous group of skin lymphomas, with Mycosis Fungoides (MF) and Sézary Syndrome (SS) being the most common subtypes. Despite various treatment options, advanced stages of CTCL often present a challenge, with limited long-term therapeutic success. Mogamulizumab has demonstrated promise in treating relapsed or refractory CTCL.Clinical trials have shown that mogamulizumab effectively targets CCR4-positive malignant T-cells, leading to tumor regression and improved survival in patients with advanced CTCL. Its ability to deplete malignant T-cells, alongside its immunomodulatory effects, contributes to its potential as a critical therapeutic agent in this setting. In both, Phase III and real-world evidence studies, mogamulizumab has demonstrated an impressive overall response rate, progression-free survival in patients with MF and SS, along with a manageable safety profile.As a promising treatment option for patients with relapsed or refractory CTCL, mogamulizumab is currently being investigated in several ongoing clinical trials, exploring its efficacy both, as a monotherapy and in combination with other treatments. Continued research and long-term follow-up are essential to optimize its application across diverse clinical settings in CTCL.